5. Any of the following: Drugs or other products known to be strong or moderate inhibitors/inducers of CYP3A4/5, or CYP3A4/5 sensitive substrates or substrates with a narrow therapeutic range. Drugs that are sensitive substrates of the transporters P-gp, BCRP, OATP1B1, OAT3, MATE1 and MATE2K.